Cargando…

LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent

Several cationic antimicrobial peptides demonstrate promising anticancer effects. We have recently described the anticancer properties of LTX-315, a novel synthetic anticancer peptide, against syngeneic B16 melanomas. LTX-315 induced a complete regression of B16 melanomas and systemic protective imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Camilio, Ketil André, Rekdal, Øystein, Sveinbjörnsson, Baldur
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4108458/ https://www.ncbi.nlm.nih.gov/pubmed/25083333 http://dx.doi.org/10.4161/onci.29181

Ejemplares similares

Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315
por: Camilio, Ketil André, et al.
Publicado: (2014)

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
por: Camilio, Ketil A., et al.
Publicado: (2019)

Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model
por: Nestvold, Janne, et al.
Publicado: (2017)

Intratumoral treatment of one tumor lesion with LTX-315 induces complete tumor regression and long-term specific protective immune responses in a metastatic rodent tumor model
por: Rekdal, Öystein, et al.
Publicado: (2014)

LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells
por: Yamazaki, Takahiro, et al.
Publicado: (2021)

Anticancer effect obtained against MCA205 sarcoma following treatment with the oncolytic peptide LTX-315 in combination with immune checkpoint inhibitors
por: Rekdal, Öystein, et al.
Publicado: (2015)

The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells
por: Eike, Liv-Marie, et al.
Publicado: (2015)

The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma
por: Eike, Liv-Marie, et al.
Publicado: (2016)

The Novel Oncolytic Compound LTX-401 Induces Antitumor Immune Responses in Experimental Hepatocellular Carcinoma
por: Mauseth, Brynjar, et al.
Publicado: (2019)

LTX-315 sequentially promotes lymphocyte-independent and lymphocyte-dependent antitumor effects
por: Liao, Hsin-Wei, et al.
Publicado: (2019)

LTX-315 – a promising novel antitumor peptide and immunotherapeutic agent
por: Zweytick, Dagmar
Publicado: (2019)

The oncolytic peptide LTX-315 triggers immunogenic cell death
por: Zhou, H, et al.
Publicado: (2016)

Cell cycle progression data on human skin cancer cells with anticancer synthetic peptide LTX-315 treatment
por: Santa-González, Gloria A., et al.
Publicado: (2020)

The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization
por: Zhou, Heng, et al.
Publicado: (2015)

Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
por: Fleten, Karianne Giller, et al.
Publicado: (2021)

Biophysical Characterization of LTX-315 Anticancer Peptide Interactions with Model Membrane Platforms: Effect of Membrane Surface Charge
por: Koo, Dong Jun, et al.
Publicado: (2022)

Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report
por: Jebsen, Nina Louise, et al.
Publicado: (2019)

Understanding the Biophysical Interaction of LTX-315 with Tumoral Model Membranes
por: Klaiss-Luna, Maria C., et al.
Publicado: (2022)

MicroRNAs as novel immunotherapeutics
por: Heimberger, Amy B, et al.
Publicado: (2013)

Immunotherapeutic implications of the immunophenotype of pediatric brain tumors
por: Griesinger, Andrea M, et al.
Publicado: (2014)

Overcoming immunosuppression as a new immunotherapeutic approach against pancreatic cancer
por: Bazhin, Alexandr V, et al.
Publicado: (2013)

An immunotherapeutic intervention against tumor progression: Targeting a driver of the epithelial-to-mesenchymal transition
por: Palena, Claudia, et al.
Publicado: (2014)

Immune mediated mechanisms of melanocyte destruction: Paving the way for efficient immunotherapeutic strategies against melanoma
por: Speeckaert, Reinhart, et al.
Publicado: (2012)

A novel system for cloning human TCRs: Cutting short the way to TCR-based anticancer therapy
por: Kobayashi, Eiji, et al.
Publicado: (2014)

Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard
por: Hailemichael, Yared, et al.
Publicado: (2013)

High-affinity peptide-based anticancer vaccination to overcome resistance to immunostimulatory antibodies
por: Binder, David C, et al.
Publicado: (2013)

Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination
por: Dosset, Magalie, et al.
Publicado: (2013)

Interventional Oncolytic Immunotherapy with LTX-315 for Residual Tumor after Incomplete Radiofrequency Ablation of Liver Cancer
por: Zhou, Guanhui, et al.
Publicado: (2022)

Cellular senescence enhances adaptive anticancer immunosurveillance
por: Marin, Ines, et al.
Publicado: (2022)

A mitochondrial checkpoint to adaptive anticancer immunity
por: Kepp, Oliver, et al.
Publicado: (2023)

Multifunctional γδ T cells and their receptors for targeted anticancer immunotherapy
por: Scheper, Wouter, et al.
Publicado: (2013)

Zoledronate-pulsed dendritic cell-based anticancer vaccines
por: Kamigaki, Takashi, et al.
Publicado: (2013)

Parvoviruses-tools to fine-tune anticancer immune responses
por: Grekova, Svitlana P., et al.
Publicado: (2012)

The anticancer effects of HDAC inhibitors require the immune system
por: West, Alison C, et al.
Publicado: (2014)

MAGE-A3-specific anticancer immunotherapy in the clinical practice
por: Brichard, Vincent G, et al.
Publicado: (2013)

ATM activation mediates anticancer immunosurveillance by natural killer and T cells
por: Tang, Melissa LF, et al.
Publicado: (2013)

Boosting anticancer vaccines: Too much of a good thing?
por: Ricupito, Alessia, et al.
Publicado: (2013)

Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy
por: Ma, Yuting, et al.
Publicado: (2014)

An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
por: Senovilla, Laura, et al.
Publicado: (2013)

Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis
por: Tang, Tianyu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6jskmv6l3ms2dcgbtf4cbaj88p